Cleminorexton for Narcolepsy

This trial tests a new treatment called cleminorexton for individuals with narcolepsy, a condition causing extreme daytime sleepiness. The goal is to determine if cleminorexton can reduce sleepiness and other symptoms. The trial includes different groups for Narcolepsy Type 1 (with cataplexy) and Type 2 (without cataplexy). Individuals who frequently experience excessive daytime sleepiness and have a narcolepsy diagnosis may be suitable candidates. As a Phase 2 and Phase 3 trial, this research measures the treatment's effectiveness in an initial, smaller group and represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

Yes, you will need to stop taking all medications used for the treatment of narcolepsy to participate in the trial.

Studies have shown that cleminorexton is generally well-tolerated by people with narcolepsy. Research indicates that this treatment, which mimics a brain protein called orexin, is safe for most users. Some reported side effects, such as trouble sleeping and increased urination, were usually mild and temporary. Thus, while some individuals may experience these effects, they are not typically severe or long-lasting. Additionally, cleminorexton has effectively helped people with narcolepsy feel more awake during the day.¹²³⁴⁵

Most treatments for narcolepsy focus on managing symptoms with stimulants like modafinil or sodium oxybate, which primarily promote wakefulness or improve nighttime sleep. But Cleminorexton works differently, targeting orexin receptors in the brain to directly address the root cause of narcolepsy. Researchers are excited about Cleminorexton because it offers a new mechanism of action that could potentially provide more effective and longer-lasting relief for narcolepsy symptoms compared to current options. This innovative approach has the potential to significantly improve the quality of life for those with narcolepsy by addressing the underlying neurological dysfunction.

Research has shown that treatments similar to cleminorexton, such as oveporexton and alixorexton, yield promising results for narcolepsy. Specifically, studies found that oveporexton significantly reduced excessive daytime sleepiness in individuals with narcolepsy type 1 and also alleviated cataplexy, a condition where emotions trigger sudden muscle weakness. Alixorexton improved wakefulness and reduced daytime sleepiness in those with narcolepsy type 2. These findings suggest that targeting orexin receptors, which help maintain wakefulness, can effectively reduce symptoms in people with narcolepsy. Participants in this trial will receive varying doses of cleminorexton or a placebo to evaluate its effectiveness for both narcolepsy type 1 and type 2.³⁶⁷⁸⁹